CNR Institutional Research Information System

ZANNETTI, ANTONELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.851
NA - Nord America 1.047
EU - Europa 540
SA - Sud America 377
AF - Africa 30
OC - Oceania 2
Totale 3.847
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 999
SG - Singapore 796
CN - Cina 399
BR - Brasile 301
VN - Vietnam 202
IT - Italia 192
HK - Hong Kong 186
FR - Francia 108
NL - Olanda 74
KR - Corea 68
FI - Finlandia 44
JP - Giappone 43
BD - Bangladesh 42
IN - India 33
DE - Germania 28
GB - Regno Unito 28
AR - Argentina 26
CA - Canada 17
MX - Messico 15
PL - Polonia 14
IL - Israele 12
CL - Cile 11
CO - Colombia 11
EC - Ecuador 11
UA - Ucraina 10
ZA - Sudafrica 9
ID - Indonesia 8
IQ - Iraq 8
PK - Pakistan 8
UZ - Uzbekistan 8
ES - Italia 7
SA - Arabia Saudita 7
PY - Paraguay 6
RU - Federazione Russa 6
TR - Turchia 6
VE - Venezuela 5
EG - Egitto 4
LT - Lituania 4
LV - Lettonia 4
MA - Marocco 4
AT - Austria 3
AZ - Azerbaigian 3
DZ - Algeria 3
IE - Irlanda 3
KE - Kenya 3
PE - Perù 3
PH - Filippine 3
UY - Uruguay 3
AU - Australia 2
BB - Barbados 2
BE - Belgio 2
BH - Bahrain 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
JO - Giordania 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
SE - Svezia 2
SI - Slovenia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GP - Guadalupe 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
LK - Sri Lanka 1
MG - Madagascar 1
MO - Macao, regione amministrativa speciale della Cina 1
MR - Mauritania 1
MY - Malesia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SD - Sudan 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
Totale 3.847
Salva come PNG Salva come JPEG
Città #
Singapore 492
Santa Clara 369
Hong Kong 185
Hefei 146
San Jose 138
Beijing 92
Lauterbourg 89
Ashburn 83
Ho Chi Minh City 70
Seoul 67
Los Angeles 62
Dallas 48
Hanoi 40
Naples 39
Tokyo 33
Afragola 23
New York 21
São Paulo 20
Lappeenranta 17
Council Bluffs 14
Marigliano 14
Helsinki 13
Turku 13
Rio de Janeiro 12
Rome 12
Belo Horizonte 11
Buffalo 11
Casandrino 10
Warsaw 10
Brooklyn 9
Frankfurt am Main 9
Giugliano in Campania 9
Da Nang 8
Falkenstein 8
Minamishinagawa 8
Tashkent 8
Bengaluru 7
Milan 7
Munich 7
Orem 7
Soccavo 7
Montreal 6
Chicago 5
Fortaleza 5
Manchester 5
Ninh Bình 5
Riga 5
Shanghai 5
Sorocaba 5
Thái Bình 5
Bari 4
Biên Hòa 4
Brasília 4
Can Tho 4
Curitiba 4
Denver 4
Dhaka 4
Ercolano 4
Guangzhou 4
Guayaquil 4
Haiphong 4
London 4
Paris 4
Phoenix 4
Quito 4
Santiago 4
Springfield 4
Amsterdam 3
Ankara 3
Baghdad 3
Baku 3
Bauru 3
Campos dos Goytacazes 3
Cape Town 3
Casablanca 3
Chennai 3
Dongguan 3
Dublin 3
Duque de Caxias 3
Elk Grove Village 3
Houston 3
Hyderabad 3
Jeddah 3
Johannesburg 3
Kyiv 3
Lahore 3
Lima 3
Limeira 3
Marília 3
Mexico City 3
Miami 3
Mumbai 3
Nanjing 3
Nha Trang 3
Niterói 3
Poplar 3
Porto Alegre 3
Praia Grande 3
Quảng Ngãi 3
Riyadh 3
Totale 2.461
Salva come PNG Salva come JPEG
Nome #
Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion 118
Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies 108
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells 87
Therapeutic Potential of a Novel alpha(v)beta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type 81
In vivo imaging of CNS microglial activation/macrophage infiltration with combined [F-18]DPA-714-PET and SPIO-MRI in a mouse model of relapsing remitting experimental autoimmune encephalomyelitis 78
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors 76
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer 75
PET imaging of brain TSPO expression in a mouse model of Experimental Autoimmune Encephalomyelitis using [18F]DPA-714 72
Optimization of Short RNA Aptamers for TNBC Cell Targeting 72
The phosphatase Shp1 interacts with and dephosphorylates cortactin to inhibit invadopodia function 69
Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFR? Aptamer. Theranostics. 67
Gefitinib, a selective, tyrosine kinase inhibitor increases 99mTc-MIBI uptake in Bcl-2 overexpressing breast cancer cells. 65
Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells 64
A Novel Inhibitor of Carbonic Anhydrases Prevents Hypoxia-Induced TNBC Cell Plasticity 62
Inhibition of Bone Marrow-Mesenchymal Stem Cell-Induced Carbonic Anhydrase IX Potentiates Chemotherapy Efficacy in Triple-Negative Breast Cancer Cells 59
Preclinical Imaging Evaluation of miRNAs' Delivery and Effects in Breast Cancer Mouse Models: A Systematic Review 56
Imaging of alpha(v)beta(3) integrin expression with a 18F-labeled RGD peptide and microPET 55
Tissue Inhibitor of Metalloproteinases-1 Overexpression Mediates Chemoresistance in Triple-Negative Breast Cancer Cells 55
New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer 55
New and selective radiolabeled alpha(v)beta(3) antagonist as tracer in tumor diagnosis 54
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases 54
In vivo imaging and characterization of [18F]DPA-714, a potential new TSPO ligand, in mouse brain and peripheral tissues using small-animal PET 53
Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0 52
Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis 52
Editorial: Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression 49
Bone Marrow uptake of 99mTc-MIBI in patients with multiple myeloma 49
Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFR? Aptamer 48
Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer 48
Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype 48
A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion 47
Aptamer-mediated impairment of EGFR-integrin alpha v beta 3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers 46
Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer 45
18F-FLT PET/CT to guide therapy with EGFR antagonists and Bcl-xL inhibitors in non-small cell lung cancer. 45
Autocrine signals increase ovine mesenchymal stem cells migration through Aquaporin-1 and CXCR4 overexpression 45
IN VITRO AND IN VIVO EVALUATION OF 111In-DTPAGlu-G-CCK8 FOR CHOLECYSTOKININ-B RECEPTOR IMAGING. 44
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer 43
TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities 42
PET/CT in cancer research: from preclinical to clinical applications 40
IN VIVO IMAGING OF ALPHA(V)BETA(3) INTEGRIN EXPRESSION WITH A RADIOLABELED CHIMERIC RDG PEPTIDE 40
Effects of Thyroid Blockade on Brain Imaging of Dopamine Transporter in Normal Mice 40
Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRbeta aptamer 40
In Vitro and In Vivo Evaluation of 111In- DTPAGlu-G-CCK8 for Cholecystokinin-B Receptor Imaging 39
Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: feasibility, optimization and validation. 39
Role of Aquaporins in the Physiological Functions of Mesenchymal Stem Cells 38
Inhibition of AQP1 Hampers Osteosarcoma and Hepatocellular Carcinoma Progression Mediated by Bone Marrow-Derived Mesenchymal Stem Cells 38
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 38
99mTc-MIBI in the evaluation of breast cancer biology 38
Chemical Modification for Proteolytic Stabilization of the Selective alpha(v)beta(3) Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells 37
inhibition of bone marrow-derived mesenchymal stem cells homing towards triple-negative breast cancer microenvironment using an anti-PDGFRbeta aptamer 37
MIBI as prognostic factor in breast cancer. 35
Functional imaging of multidrug resistance in breast cancer 35
Radiolabeling approaches for cholecystokinin B receptor imaging 34
Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells 33
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma 32
Novel and selective αvβ3 receptor peptide antagonist: Design, synthesis, and biological behavior 32
99mTc-MIBI in the evaluation of breast cancer biology 31
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 30
Nuclear imaging in cancer theranostics 30
In vivo imaging of alpha(v)beta(3) integrin expression with a radiolabeled chimeric RGD peptide 30
Molecular imaging of drug resistance in cancer 30
High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma 29
Dynamic coupling of 99mtc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 29
A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth 28
A RADIOLABELING SYNTHESIS OF RGD ECHI WITH 18FLUORIDE- 28
Small animal SPECT with 99m-Tc-Hynic-annexin V for detection of non-small cell lung cancer resistance to EGFR antagonists and its reversal by Bcl-xL inhibitors 28
A New and selective radiolabeled alphavbeta3 peptide antagonist as tracer in tumor diagnosis 28
A NEW AND SELECTIVE RADIOLABELED ALPHAVBETA3 PEPTIDE ANTAGONIST AS TRACER IN TUMOR DIAGNOSIS. 28
Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. 28
18F-FLT PET/CT to guide therapy with EGFR antagonists and Bcl-xL inhibitors in non-small cell lung cancer 27
MicroPET/CT of mice bearing alpha(v)beta(3)-expressing tumors by a 18F-labeled bifunctional chimeric RGD peptide 27
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-X-L modulation of inositol trisphosphate receptor type 3 27
IMAGING IN VIVO DELL'ESPESSIONE DELL'INTEGRINA alfa(v)beta(3) CON UN PEPTIDE CHIMERICO RGD RADIOMARCATO 27
AN IMPROVED RADIOLABELING SYNTHESIS OF RGDECHI WITH 18F-FLUORIDE. 27
Stato dell'arte dell'imaging preclinico in oncologia 27
A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors 27
Imaging of alpha(v)beta(3) integrin expression with a 18F-labeled RGD peptide and microPET 27
Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype 26
Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer 26
Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer 26
Inhibition of early (99m)Tc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma 26
Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines 26
In Vitro and In Vivo Evaluation of 111In- DTPAGlu-G-CCK8 for Cholecystokinin-B Receptor Imaging 25
Novel and selective alpha v beta 3 receptor peptide antagonist: Design, synthesis and biological behaviour 25
Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models 24
Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. 23
PET/CT in cancer research: from preclinical to clinical applications 23
New and selective radiolabeled alphavbeta3 peptide antagonist as tracer in tumor diagnosis 23
Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer 22
Coordinate upregulation of Sp1 DNA binding activity and urokinase receptor expression in breast carcinoma 22
High Frequency Ultrasound for the development of an Orthotopic mouse model of Human Follicular Thyroid Carcinoma 22
Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRB aptamer 21
Molecular imaging of tumor microenvironment: challenges and perspectives 21
A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling 20
Elevated Expression of the Tyrosine Phosphatase SHP-1 Defines a Subset of High-Grade Breast Tumors 19
Urokinase Receptor Interacts with avb5 Vitronectin Receptor, Promoting Urokinase-dependent Cell Migration in Breast Cancer 18
A NEW AND SELECTIVE RADIOLABELLED v 3 PEPTIDE ANTAGONIST AS TRACER IN TUMOR DIAGNOSIS 16
Longitudinal evaluation with High Frequency Ultrasound imaging of response to CXCR4 new cyclic peptide antagonist with conventional chemotherapy in colorectal cancer mice model 16
Totale 3.966
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.505
article - articoli 10.922
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 222
Totale 23.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202443 0 0 0 0 0 0 0 0 1 5 22 15
2024/20251.626 26 13 165 57 368 77 40 70 85 93 338 294
2025/20262.297 106 280 188 320 414 102 368 97 147 144 131 0
Totale 3.966